Assistant Professor in the Department of Epidemiology and Population Health at Albert Einstein College of Medicine @EinsteinMed. Opinions are my own.
Bronx, NY
Joined December 2018
- Tweets724
- Following379
- Followers284
- Likes294
Pinned Tweet
Day 1 @EinsteinMed: Excited to embark on a new chapter as an Assistant Professor in the Department of Epidemiology and Population Health at Albert Einstein College of Medicine!
Look forward to working independently and collaborating with brilliant minds at/beyond Einstein!
As a cancer researcher, one of my most thankful experiences is to work with a cancer survivor/advocate like Debbie Denardi @debsetu .
Read her story (cancertodaymag.org/fall-2026…) to learn more about her inspiring cancer journey in diagnosis, treatment, advocacy, and research.
NIH impact score/percentile will be replaced with 3 categories:
"Most competitive" (top 25%),
"Competitive" (26-50%),
"Not discussed" (scores >50%).
Read more details 👉grants.nih.gov/grants/guide/…
Many thanks to my institution Albert Einstein College of Medicine @EinsteinMed for featuring my recent NCI K01 Award!
montefioreeinstein.org/news/…
🗓️May 28, 2026, 11:30 a.m.–1:00 p.m. ET for an NCI Cohort Consortium Webinar “Artificial Intelligence in Epidemiology: Tools & New Technologies for Cohort Studies”
Register👉epi.grants.cancer.gov/cohort…
Excited to co-moderate this timely discussion on AI, epidemiology, and cohorts!
En Cheng retweeted
Congratulations to Alliance researchers presenting at #AACR2026. Highlights include advancing early phase trial design, uncovering AML mutations tied to survival, and showing that healthy lifestyle can improve colon cancer outcomes during chemo. bit.ly/AACR-Alliance26
#AACR26 Come to my poster (Section #35 Poster #11) on 4/21 (Tuesday) 9AM-12PM PST @AACR!
Using Alliance data (CALGB/SWOG 80702), I will present the findings how adhering to WCRF/AICR Recommendations may improve colon cancer survival and impact chemotherapy outcomes.
Congratulations to Alliance researchers presenting at #AACR2026. Highlights include advancing early phase trial design, uncovering novel AML mutations tied to survival, and showing that healthy lifestyle adherence improves colon cancer outcomes during chemo. Proud of their work!
En Cheng retweeted
Our paper in how AI is answering cancer -related questions in Spanish. Collabotion with Dr @EnCheng23 and Dr @jesusanampa
👇🔗
onlinelibrary.wiley.com/doi/…
AI is typically trained on English materials, and their performance in Spanish cancer questions is unknown. We assessed 3 popular AI chatbots (ChatGPT, Gemini, Claude) and found they generated good-quality responses, regardless of free vs paywall versions. dx.doi.org/10.1002/cam4.7136…
Special thanks to my colleagues - Dr. @jesusanampa and Dr. @BernabeCarolina (native Spanish-speaking oncologists) - who have done a terrific job in evaluating Spanish responses generated from AI chatbots!
AI is typically trained on English materials, and their performance in Spanish cancer questions is unknown. We assessed 3 popular AI chatbots (ChatGPT, Gemini, Claude) and found they generated good-quality responses, regardless of free vs paywall versions. dx.doi.org/10.1002/cam4.7136…
AI is typically trained on English materials, and their performance in Spanish cancer questions is unknown. We assessed 3 popular AI chatbots (ChatGPT, Gemini, Claude) and found they generated good-quality responses, regardless of free vs paywall versions. dx.doi.org/10.1002/cam4.7136…
Sex (as a biological variable) may affect chemo completion, toxicities, and cancer survival differently. Our findings @JNCI_Now suggested females with colon cancer have worse chemo completion and more toxicites than males, but females have better survival. academic.oup.com/jnci/advanc…
I'm deeply honored and humbled to be recognized for this award by Alliance!
Kudos to .@EnCheng23, of the @EinsteinMed for one of the Most Significant @ALLIANCE_org Manuscripts 2024-2025! "Plant-based Diet and Survival Among - Patients with Metastatic Colorectal Cancer" in @JNCI_Now #AllianceFall25 #NCI #NCTN #CALGB-80405 #SWOG-80405
En Cheng retweeted
In patients with localized colorectal cancer and PIK3CA hotspot mutations in exon 9 or 20, daily low-dose aspirin resulted in a significantly lower recurrence rate than placebo. ALASCCA phase 3 trial results: nej.md/4mpKXNp
Editorial: An Aspirin a Day for Improved Colorectal Cancer Outcomes nej.md/42gHolx
ALT Original Article | Sep. 18, 2025 Low-Dose Aspirin for PI3K-Altered Localized Colorectal Cancer (ALASCCA) Figure 2A. Colorectal Cancer Recurrence among Patients with Group A Alterations
From @Nature: Can creativity in science be learnt? These researchers think so.
nature.com/articles/d41586-0…
NCI FY25 Payline
R01: 4th percentile for EI/NI and 10th percentile for ESI.
R21: 7th percentile.
R03: score ≤25.
cancer.gov/grants-training/g…
Early grant success attracts more funding: study of 100,000 applicants hints at why nature.com/articles/d41586-0…
En Cheng retweeted
Thank you @ASCO for the opportunity to present our work. Incredibly grateful to @KimmieNgMD and Chen Yuan for their mentorship @DanaFarber
.@sarakcharMD presents intriguing findings on how diet impacts survival in stage III colon cancer patients. The study examines the link between dietary inflammation and outcomes, offering insights into nutrition's role in cancer care. #ASCO25
